ArticleClinical rheumatology2024
Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases.
Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Risk factors for mortality in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Determinants for worsening in systemic autoimmune rheumatic disease-associated interstitial lung disease: a systematic review and meta-analysis of cohort studies.Frontiers in medicine · 2024Pooled it
- Semiquantitative HRCT scoring: a reliable predictor of rapidly progressive interstitial lung disease in patients with anti-MDA5 positive dermatomyositis.Quantitative imaging in medicine and surgery · 2026Article
- Clinical characteristics and outcomes of anti-MDA5 dermatomyositis: a retrospective study.BMC rheumatology · 2025Article
- Clinical features and prognosis of anti-MDA5-positive dermatomyositis with coexistent anti-aminoacyl-tRNA synthetase antibodies.Clinical rheumatology · 2025Article
- Different antinuclear antibody subgroups of anti-melanoma differentiation-associated gene 5-positive dermatomyositis showed variability in clinical presentation: a multicenter retrospective cohort study.Archives of medical science : AMS · 2025Article
- Serum lactate dehydrogenase and rapidly progressive interstitial lung disease are associated with increased mortality in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.Frontiers in immunology · 2025Article
- Sex-based differences in dermatomyositis: a retrospective study.Archives of dermatological research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 14 institutions in 1 country.
Funding
Abstract
objectiveTo investigate the impact of sex differences on the clinical characteristics and prognosis of patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5
methodsWe retrospectively analyzed a cohort of 251 patients with MDA5
resultsPatients in the male group had a significantly higher prevalence of heliotrope rash, V sign, severe interstitial lung disease (ILD), and rapidly progressive interstitial lung disease (RPILD) than those in the female group. Anti-Ro52 positivity, high CRP level and short disease were identified as independent risk factors for RPILD in both male and female groups by multivariate logistic regression analysis. The mortality rates of males and females were 33.8% and 22.0%, respectively, and the survival time of patients in the male group was shorter than that in the female group.
conclusionMale patients with MDA5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.